A5025353450- Mosquito-borne diseases and control
- Viral Infections and Vectors
- Hepatitis Viruses Studies and Epidemiology
- Liver Disease and Transplantation
- Viral Infections and Outbreaks Research
- Vibrio bacteria research studies
- Malaria Research and Control
- Viral gastroenteritis research and epidemiology
- Hepatitis B Virus Studies
- Cytomegalovirus and herpesvirus research
- Vaccine Coverage and Hesitancy
- Parvovirus B19 Infection Studies
- COVID-19 Clinical Research Studies
- Blood groups and transfusion
- COVID-19 epidemiological studies
- Virology and Viral Diseases
- Virus-based gene therapy research
- Viral-associated cancers and disorders
- SARS-CoV-2 and COVID-19 Research
- Erythrocyte Function and Pathophysiology
- Travel-related health issues
- Retinal and Optic Conditions
- Blood transfusion and management
- Herpesvirus Infections and Treatments
Royal Children's Hospital
2024
Murdoch Children's Research Institute
2024
Australian Red Cross Lifeblood
2012-2022
Melbourne Health
2022
The University of Melbourne
2020
The Royal Melbourne Hospital
2020
Peter Doherty Institute
2020
Immungenetics (Germany)
2017
Iowa City Public Library
2016
Seattle University
2016
Dengue outbreaks have increased in size and frequency Australia, transfusion-transmitted dengue poses a risk to transfusion safety. Using whole blood samples collected during the large 2008-2009 epidemic, we estimated for dengue-infectious donation as ≈1 7,146 (range 2,218-50,021).
BACKGROUND Arboviruses, including dengue (DENV 1‐4), chikungunya (CHIKV), and Ross River (RRV), are emerging viruses that a risk for transfusion safety globally. An approach managing this is pathogen inactivation, such as the THERAFLEX UV‐Platelets system. We investigated ability of system to inactivate above mentioned arboviruses. STUDY DESIGN AND METHODS DENV 1‐4, CHIKV, or RRV were spiked into buffy coat (BC)‐derived platelet (PLT) concentrates in additive solution treated with at...
Dengue viruses (DENV 1-4) are emerging across the world, and these pose a risk to transfusion safety. Pathogen inactivation may be an alternative approach for managing of DENV transmission. This study aimed investigate ability riboflavin UV light inactivate 1-4 in platelet concentrates.DENV were spiked into buffy coat-derived concentrates additive solution (SSP+) before being treated with light. Infectious virus was quantified pre- posttreatment, reduction viral infectivity calculated.All...
BACKGROUND Zika virus (ZIKV) has emerged as a potential threat to transfusion safety worldwide. Pathogen inactivation is one approach manage this risk. In study, the efficacy of THERAFLEX UV‐Platelets system and MB‐Plasma inactivate ZIKV in platelet concentrates (PCs) plasma was investigated. STUDY DESIGN AND METHODS PCs spiked with were treated at 0.05, 0.10, 0.15, 0.20 J/cm 2 UVC. Plasma 20, 40, 60, 120 light 630 nm least 0.8 µmol/L methylene blue (MB). Samples taken before first after...
Hepatitis E virus (HEV) is a known transfusion-transmissible agent. HEV infection has increased in prevalence many developed nations with RNA detection donors as high 1 600. A proportion of infections are asymptomatic and therefore not interdicted by donor exclusion criteria. To manage the transfusion-transmission (TT) risk some have implemented screening. In Australia, rarely notified; although locally acquired been reported, burden disease unknown. The purpose this study was to determine...
Background Arboviruses are an emerging threat to transfusion safety and rates of infection likely increase with the increased rainfall associated climate change. Arboviral infections common in A ustralia, where R oss iver virus ( RRV ), B armah F orest BFV M urray V alley encephalitis MVEV among others, have potential cause disease humans. The use pathogen reduction technology PRT ) may be alternative approach for blood services manage risk arboviral transmission. In this study,...
BACKGROUND Arboviruses, such as dengue viruses (DENV) and chikungunya virus (CHIKV), pose a risk to the safe transfusion of blood components, including plasma. Pathogen inactivation is an approach manage this transmission risk, with number techniques being used worldwide for treatment In study, efficacy THERAFLEX MB‐Plasma system inactivate all DENV serotypes (DENV‐1, DENV‐2, DENV‐3, DENV‐4) or CHIKV in plasma, using methylene blue light illumination at 630 nm, was investigated. STUDY DESIGN...
BACKGROUND Yellow fever virus (YFV) is endemic to tropical and subtropical areas in South America Africa, currently a major public health threat Brazil. Transfusion transmission of the yellow vaccine has been demonstrated, which indicative potential for viral transfusion transmission. An approach manage YFV risk use pathogen inactivation (PI) technology systems, such as THERAFLEX MB‐Plasma UV‐Platelets (Macopharma). We aimed investigate efficacy these PI systems inactivate plasma or platelet...
Adequate preparation and support for healthcare workers (HCWs) managing high-consequence infectious diseases (HCIDs) is critical to the overall clinical management of HCIDs. Qualitative studies examining how well prepared supported HCWs feel are lacking despite their key role. This study investigated front-line at an Australian tertiary hospital felt about HCIDs such as viral haemorrhagic fever (VHF).A qualitative research approach was used undertake interviews with 45 Royal Melbourne...
Dengue viruses (DENV 1-4) are a risk to transfusion safety, with several transfusion-transmitted (TT) cases reported globally. DENV 1-4 endemic in over 100 countries, seasonal outbreaks occurring northeastern Australia. To mitigate TT-DENV Australia, fresh blood components not manufactured from donors returning any area (domestic/overseas) known dengue transmission. Alternatively, may be mitigated using an appropriate donor screening assay. We aimed determine the rate of infection during...
Human herpesvirus 8 (HHV-8), the causative agent of Kaposi’s sarcoma, multicentric Castleman’s disease and primary effusion lymphoma, predominantly manifests in immunocompromised individuals. However, infection immunocompetent individuals does occur. The prevalence HHV-8 exposure blood donors from non-endemic countries ranges between 1.2% 7.3%. Nothing was known about Australian donors. Therefore, this study investigated active cumulative cohort. Plasma samples (n = 480) were collected...